- Home
- FFIC vs RIGL Comparison
FFIC vs RIGL Comparison
Compare FFIC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIC
- RIGL
- Stock Information
- Founded
- FFIC 1929
- RIGL 1996
- Country
- FFIC United States
- RIGL United States
- Employees
- FFIC N/A
- RIGL N/A
- Industry
- FFIC Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FFIC Finance
- RIGL Health Care
- Exchange
- FFIC Nasdaq
- RIGL Nasdaq
- Market Cap
- FFIC 401.3M
- RIGL 335.5M
- IPO Year
- FFIC 1995
- RIGL 2000
- Fundamental
- Price
- FFIC $12.61
- RIGL $20.05
- Analyst Decision
- FFIC Hold
- RIGL Buy
- Analyst Count
- FFIC 3
- RIGL 5
- Target Price
- FFIC $16.17
- RIGL $36.40
- AVG Volume (30 Days)
- FFIC 299.2K
- RIGL 201.8K
- Earning Date
- FFIC 07-24-2025
- RIGL 08-05-2025
- Dividend Yield
- FFIC 7.01%
- RIGL N/A
- EPS Growth
- FFIC N/A
- RIGL N/A
- EPS
- FFIC N/A
- RIGL 2.08
- Revenue
- FFIC $124,028,000.00
- RIGL $203,077,000.00
- Revenue This Year
- FFIC $110.74
- RIGL $14.41
- Revenue Next Year
- FFIC $7.28
- RIGL $15.97
- P/E Ratio
- FFIC N/A
- RIGL $9.63
- Revenue Growth
- FFIC N/A
- RIGL 70.16
- 52 Week Low
- FFIC $10.65
- RIGL $8.61
- 52 Week High
- FFIC $18.59
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- FFIC 57.47
- RIGL 52.77
- Support Level
- FFIC $11.84
- RIGL $18.66
- Resistance Level
- FFIC $12.69
- RIGL $19.85
- Average True Range (ATR)
- FFIC 0.27
- RIGL 0.68
- MACD
- FFIC 0.02
- RIGL 0.08
- Stochastic Oscillator
- FFIC 75.25
- RIGL 80.12
About FFIC Flushing Financial Corporation
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.